On Thursday, American Express Company (NYSE:AXP)’s shares declined -0.34% to $77.06.
American Express (AXP) declared that international recording artists Disclosure and actor, writer and television host James Corden have been selected as the next pairing in its popular live stream music series “American Express Unstaged,” in partnership with Vevo and YouTube. Disclosure’s September 29 concert from Los Angeles Sports Arena at 9:00 PM PT will be executive produced by Corden and will be live streamed at amexunstaged.com and via the Unstaged app. The performance is set to take place just days after the release of Disclosure’s sophomore album “Caracal” with the Unstaged performance being their first full live show featuring tracks off their new album.
James Corden is a triple threat starring on stage, film, and television. He’s known around the world as a Tony Award®-winning performer on Broadway, a BAFTA-winning star of a UK television series, a feature film actor, and an acclaimed host, writer, and producer in several genres of television. Since Corden took over as host of the hit CBS staple “THE LATE LATE SHOW” on March 23, 2015, the show has generated numerous buzzworthy viral videos (23 of which boast more than 1 million online views), reached series highs in viewers and earned a Critics’ Choice Awards nomination. American Express enlisted Corden on the project to lend his theatrical expertise to the production and assist create an engaging experience for fans in attendance and in addition to those viewing the live performance online.
American Express Company, together with its auxiliaries, provides charge and credit payment card products and travel-related services to consumers and businesses worldwide.
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)’s shares gained 8.22% to $10.79.
Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently declared that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections (cUTI) did not achieve its primary endpoint of statistical non-inferiority contrast to levofloxacin.
The pivotal portion of the phase 3 IGNITE2 clinical trial enrolled 908 patients who were randomized 1:1 to receive eravacycline (1.5 mg/kg intravenously every 24 hours followed by 200 mg orally every 12 hours) or levofloxacin (750 mg intravenously every 24 hours followed by 750 mg orally every 24 hours). Each patient received a minimum of 3 days of IV dosing and then, if clinically indicated, were eligible to transition to oral therapy for the remaining doses for a total treatment period of 7 days. For the U.S. Food and Drug Administration (FDA), the primary analysis evaluated the responder outcome (a combination of clinical cure rate and microbiological response) in the Microbiological Intent-to-Treat (micro-ITT) population at the Post-Treatment (PT) visit (defined as 6-8 days after the completion of therapy) using a 10% non-inferiority margin. For the European Medicines Agency (EMA), the primary analysis evaluated the microbiological response in the microbiologically modified ITT (micro-MITT) population and microbiologically evaluable (ME) populations at the PT visit using a 10% non-inferiority margin. Eravacycline did not achieve the primary endpoint under either analysis.
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate comprises eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, counting multidrug-resistant Gram-negative infections.
At the end of Thursday’s trade, Archer Daniels Midland Company (NYSE:ADM)‘s shares surged 0.14% to $44.25.
Archer Daniels Midland Company (ADM) declared that it will open in October a new, state-of-the-art flavor creation, application and customer service facility in Cranbury, New Jersey. The 15,700-square-foot site will comprise lab, office and meeting space—counting dedicated lab space for mint and oral care products—and will house a staff of flavorists and applications technologists.
“Our customers expect a lot from working with the premier flavor company in the world, and this facility will assist us continue to meet—and exceed—their needs,” said Ken Campbell, president of ADM’s WILD Flavors business. “This new facility will be easy to reach for major customers, it will feature state-of-the-art equipment and resources—counting a customer innovation center—and it will be staffed with talented, dedicated flavorists and application technologists who are ready and eager to work side by side with customers to meet their needs. This facility will assist us continue to grow WILD Flavor’s sales and ensure that we remain the first and best choice among global flavor companies.”
Archer-Daniels-Midland Company procures, transports, stores, processes, and merchandises agricultural commodities and products. The company’s Oilseeds Processing segment originates, merchandises, crushes, and processes soybeans and soft seeds into vegetable oils and protein meals.
CLARCOR Inc. (NYSE:CLC), ended its Thursday’s trading session with -13.03% loss, and closed at $48.39.
CLARCOR Inc. (CLC) stated that its diluted earnings per share for the third quarter of 2015 declined 12% from the third quarter of 2014 to $0.72. Net sales declined $42.6 million, or 11%, from last year’s third quarter, counting a decline of $13.4 million, or 3%, from changes in the average foreign currency exchange rates from last year’s third quarter.
The third quarter of 2015 comprised of a $6.7 million impairment loss from the write-off of non-core investments and a $12.1 million net gain related to the disposition of our packaging business, J.L. Clark. To allow investors to better compare and evaluate our historical financial performance, we are also presenting non-GAAP adjusted financial results in the table following this paragraph. These non-GAAP adjusted financial results for 2015 exclude the impairment loss on the non-core investments, the gain on the sale of J.L. Clark and operational results for J.L. Clark. Non-GAAP adjusted financial results for 2014 exclude certain acquisition-related items associated with the GE Air Filtration, Bekaert Advanced Filtration and Stanadyne Filtration acquisitions, and operational results for J.L. Clark. Please refer to pages 11 through 14 of this earnings release for reconciliations and additional information with respect to these non-GAAP adjusted financial results.
Chris Conway, CLARCOR’s Chairman, President and Chief Executive Officer, commented, “The third quarter was challenging from many perspectives, as most of our primary end-markets were negatively influenced by various macroeconomic pressures that proved to be much stronger than we had anticipated heading into the quarter and resulted in lower than predictable net sales. Lower net sales contributed significantly to lower third quarter 2015 operating margin as we were not able to leverage additional growth-related manufacturing and administrative costs. Third quarter 2015 non-GAAP adjusted net sales—after removing sales from our packaging business from all periods—declined about 7% from last year’s third quarter, with about 3% of this reduction due to lower average foreign currency exchange rates. This net sales decline was heavily influenced by pressures in our gas turbine first-fit, heavy-duty engine export and heavy-duty engine off-road markets.
CLARCOR Inc. provides filtration products, filtration systems and services worldwide. Its Engine/Mobile Filtration segment offers filtration systems; and oil, air, fuel, coolant, transmission, and hydraulic filters for use in trucks, agricultural machinery, construction and mining equipment, power generation, marine, automobiles, transit buses, locomotives, and other industrial and specialty applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
